Regeneron Pharmaceuticals (REGN) Cash from Financing Activities (2009 - 2026)

Regeneron Pharmaceuticals' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$802.2 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 26.35% year-over-year to -$802.2 million; the TTM figure through Mar 2026 stood at -$3.4 billion (down 2.75% YoY), while the FY2025 annual figure was -$3.7 billion, down 68.84% from the prior year.
• Cash from Financing Activities was -$802.2 million for Q1 2026 at Regeneron Pharmaceuticals, down from -$780.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $64.7 million in Q1 2022 to a low of -$1.1 billion in Q4 2024.
• Historically, Cash from Financing Activities has averaged -$559.8 million across 5 years, with a median of -$614.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities jumped 117.66% in 2022, then sank 2412.53% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$247.6 million in 2022, then sank by 80.17% to -$446.1 million in 2023, then sank by 154.54% to -$1.1 billion in 2024, then soared by 31.3% to -$780.1 million in 2025, then fell by 2.83% to -$802.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$802.2 million (Q1 2026), -$780.1 million (Q4 2025), and -$717.9 million (Q3 2025), per Business Quant data.